ProCE Banner Activity

LIBERTY AD PEDS Study Results: Efficacy and Safety of Dupilumab in Children Aged ≥ 6 to < 12 Yrs With Severe Atopic Dermatitis

Slideset Download
Conference Coverage
Severe atopic dermatitis was significantly improved for children aged ≥ 6 to < 12 years with dupilumab vs placebo. 

Released: July 20, 2020

Expiration: July 19, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

This educational activity is supported by educational grants from

AbbVie Inc.

Pfizer, Inc.